An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

NCT06315556

Status	RECRUITING
Sponsor	Bayer
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (4)

- Eligible infants within the NNRD include those who were:
- \. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
- \. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
- \. Diagnosed with ROP in any stage in at least one eye.

Exclusion (1)

- Infants with missing data for gestational age at birth will be excluded.

Locations (1 total)

Many locations, Multiple Locations, United Kingdom